Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$187.9M
27M shares
52-week range
$5.34 – $9.13
42% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
1.26%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $358.1M | $361.9M | $308.5M | $358.0M | $377.2M | $315.7M | $335.7M | $348.7M |
| Cost of revenue | $179.5M | $190.1M | $170.3M | $181.5M | $223.7M | $189.0M | $181.0M | $182.8M |
| Gross profit | $178.6M | $171.9M | $138.2M | $176.5M | $153.5M | $126.7M | $154.7M | $165.9M |
| Gross margin | 49.9% | 47.5% | 44.8% | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| R&D | $7.0M | $9.4M | $14.1M | $16.6M | $21.9M | $20.8M | $21.6M | $19.4M |
| Operating income | $37.9M | $19.8M | −$12.0M | $9.2M | −$85.2M | −$109.4M | −$42.5M | −$30.2M |
| EBITDA | $49.2M | $33.6M | $6.6M | $30.3M | −$9.6M | −$58.3M | −$15.5M | −$2.7M |
| Net income | $51.8M | $20.9M | −$5.8M | −$6.3M | −$83.8M | −$102.4M | −$35.9M | −$22.7M |
| Net margin | 14.5% | 5.8% | -1.9% | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (diluted) | 2.30 | 0.94 | -0.27 | -0.28 | -3.67 | -4.42 | -1.52 | -0.85 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $369M | $-0.78 | $-0.79–$-0.78 | 1 |
| 2027 | $397M | $-0.47 | $-0.47–$-0.46 | 1 |
| 2028 | $417M | $-0.33 | $-0.51–$-0.15 | 2 |
| 2029 | $455M | $0.05 | $0.05–$0.05 | 1 |
Forward consensus · source: Financial Modeling Prep
Inogen Inc is a medical technology business that focuses on respiratory health. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators, or POCs, used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. In addition, it has started distributing the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure, or CPAP, masks in the United States. The company derives revenues from customers through the development, manufacturing, marketing, sales, and rental of respiratory products.
www.inogen.comNo one on the platform currently holds INGN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 478,800 | $3.0M |
No one on the platform has traded INGN yet.
| $101M |
| — |
| NNOXNano-X Imaging Ltd. | $1.09 | +23.95% | $76M | — |
| OMOutset Medical, Inc. | $4.58 | -0.22% | $85M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 0.5× sales vs its 0.8× historical median P/S.
Fair value ≈ $11.41 · price $6.93 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$INGN Share Price: $6.05 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 59% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$INGN at an EV of $63M I continue to believe there is major value here
View on StockTwits ↗$INGN Q1 '26 Earnings Results & Recap Inogen expects Q2 2026 revenue of $94M to $97M and reiterates full-year 2026 revenue guidance of $366M to $373M, reflecting approximately 6.0% growth.
View on StockTwits ↗$INGN so frustrating, it actually has a strong day, then just casually drops .50 cents after hours
View on StockTwits ↗$INGN Keep in mind, It is still undervalued than book price.
View on StockTwits ↗$INGN's Q4 surprise: Narrower loss, but shares slip! 🤔 💡 Adjusted loss per share of 15 cents beat estimates, yet revenue missed slightly & shares dropped nearly 5% in after-market trading. Strong international sales couldn't offset weaker U.S. performance. Complete risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2875401/inogen-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875401-body-35194&ADID=SYND_STOCKTWITS_TWEET_2_2875401_BODY_35194
View on StockTwits ↗$INGN bests expectations and cashed up with 7M shares float. No debt.
View on StockTwits ↗$INGN beats… but the stock slips ⚠️ Q4 delivered a narrower loss and a 2% revenue rise, yet shares dipped as U.S. sales and rentals weakened — even with international strength helping offset the pressure. Is this short-term noise or a deeper issue? Get the full breakdown 👉 https://www.zacks.com/stock/news/2875401/inogen-stock-dips-despite-q4-earnings-beat-revenues-up-yy?cid=sm-stocktwits-2-2875401-teaser-35191&ADID=SYND_STOCKTWITS_TWEET_2_2875401_TEASER_35191
View on StockTwits ↗$INGN this will go higher as the Buy back gets moving. They also beat expectations last night so look for red to green and higher prices in coming days
View on StockTwits ↗$INGN $3’s incoming. Gonna get destroyed. Horrible ER. Market about to punish them.
View on StockTwits ↗$INGN: Inogen (-6.8%) has authorized a share repurchase program for up to $30 mln of its outstanding common stock
View on StockTwits ↗$INGN does $5 hold? Buyback mentioned to hide the bad ER. They used to help but not anymore. Lets see how low the market takes this today.
View on StockTwits ↗$INGN good DD. Let the share buyback support us now, 7.2 book value
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.